ClinicalTrials.gg
RecruitingNCT07575672FINE-VALUEUpdated Oct 16, 2026

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

A Phase 3 interventional study of Finerenone and Placebo in HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation) and Finerenone, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 61 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,832
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Planned enrollment
3rd of 23
2,832 · median 120
Started
2026
with 9 others
Phase 3
9 of 23
8 open now
Primary completion
2029-12
later than 13 of 16 live
Registered
21st of 23
by date

Among the 23 studies testing finerenone in Heart Failure, this one is the 3rd largest by planned enrollment, is one of 10 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 13 of the 16 other live ones, and was the 21st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure with LVEF ≥40% is associated with a reduction in the composite endpoint of all-cause mortality or worsening of heart failure. Participants are patients with symptomatic aortic stenosis undergoing TAVI and heart failure with LVEF≥40%. Eligible patients will be randomly assigned in a 1:1 ratio to either the finerenone group or the placebo group. Patients meeting all inclusion criteria and not any exclusion criteria will be invited to participate before discharge. All enrolled patients will consecutively receive treatment, during which serum potassium and estimated glomerular filtration rate will be closely monitored. Follow-up will be conducted at 30 days, 12 months at clinic, and 3 months, 6 months, 9 months and every 6 months after 12 months of enrollment online or via telephone (at clinic if necessary). The final visit will be conducted for all enrolled patients at the end of the study.

Read the detailed description

Inclusion criteria:

  1. Age ≥ 65 years.
  2. Patients with severe aortic stenosis (aortic valve area \< 1.0 cm2 or indexed area \< 0.6 cm2/m2, or mean transvalvular aortic gradient ≥ 40 mmHg or velocity of blood flow through the valve ≥ 4.0 m/s) undergoing transfemoral TAVI.
  3. New York Heart Association class ≥ II.
  4. Left ventricular ejection fraction ≥ 40% at baseline prior TAVI.
  5. Informed consent has been signed.

Exclusion criteria:

  1. Untreated serum/plasma potassium > 5.0 mmol/L during the screening period or randomization visit.
  2. Estimated glomerular filtration rate \< 25 ml/min/1.73 m².
  3. Occurred or planned to undergo: acute myocardial infarction, cardiac resynchronization therapy device implantation, stroke, or transient ischemic attack within 30 days prior to randomization.
  4. Known allergy, intolerance, or contraindication to mineralocorticoid receptor antagonists.
  5. Pregnant or breastfeeding patients.
  6. Life expectancy \< 1 year.
  7. Currently participating in a cardiovascular investigational drug or another device study and not yet completed follow-up for the primary endpoint.
03

Conditions studied

  • HFpEF - Heart Failure With Preserved Ejection Fraction
  • TAVI(Transcatheter Aortic Valve Implantation)
  • Finerenone

Browse trials for

Keywords

  • HFpEF
  • TAVI
  • Finerenone
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 65 years.
  2. Patients with severe aortic stenosis (aortic valve area \< 1.0 cm2 or indexed area \< 0.6 cm2/m2, or mean transvalvular aortic gradient ≥ 40 mmHg or velocity of blood flow through the valve ≥ 4.0 m/s) undergoing transfemoral TAVI.
  3. class ≥ II.
  4. ≥ 40% at baseline prior TAVI.
  5. has been signed.

Exclusion criteria

Exclusion Criteria:

  1. Untreated serum/plasma potassium > 5.0 mmol/L during the screening period or randomization visit.
  2. Estimated \< 25 ml/min/1.73 m².
  3. Occurred or planned to undergo: acute myocardial infarction, cardiac resynchronization therapy device implantation, stroke, or within 30 days prior to randomization.
  4. Known allergy, intolerance, or to mineralocorticoid receptor antagonists.
  5. Pregnant or breastfeeding patients.
  6. \< 1 year.
  7. Currently participating in a cardiovascular drug or another device study and not yet completed follow-up for the primary endpoint.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,832 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Oral treatment with finerenone daily: * For participants with an eGFR ≤60 mL/min/1.73 m2: Starting dose is 10 mg OD and target dose 20 mg OD. * For participants with an eGFR \>60 mL/min/1.73 m2: Starting dose is 20 mg OD and target dose 40 mg OD.

    Drug: Finerenone

  • Placebo comparator
    Control Group

    Oral treatment with placebo daily

    Drug: Placebo

Interventions

  • Oral treatment with finerenone daily: * For participants with an eGFR ≤60 mL/min/1.73 m2: Starting dose is 10 mg OD and target dose 20 mg OD. * For participants with an eGFR \>60 mL/min/1.73 m2: Starting dose is 20 mg OD and target dose 40 mg OD.

  • DrugPlacebo

    Oral treatment with placebo daily

06

What researchers measure

Primary outcomes

  1. A composite of all-cause mortality or worsening of heart failure (hospitalization for HF or urgent HF visit), any of the first occurrence during the follow-up.

    Time frame: at least 12 months

Secondary outcomes

  1. Total number of worsening of heart failure.

    Time frame: at least 12 months

  2. Total number of worsening of heart failure and cardiovascular mortality.

    Time frame: at least 12 months

  3. Total number of worsening of heart failure and all-cause mortality.

    Time frame: at least 12 months

  4. Time to cardiovascular mortality.

    Time frame: at least 12 months

  5. Time to all-cause mortality.

    Time frame: at least 12 months

  6. Time to first worsening of heart failure.

    Time frame: at least 12 months

  7. Time to cardiovascular mortality or first worsening of heart failure.

    Time frame: at least 12 months

  8. Time to cardiovascular mortality or first worsening of heart failure in patients with chronic kidney disease or diabetes.

    Time frame: at least 12 months

  9. Time to all-cause mortality or first worsening of heart failure in patients with chronic kidney disease or diabetes.

    Time frame: at least 12 months

  10. Change from baseline in KCCQ score at 30-day and 12-month follow-up.

    Time frame: 30-day and 12-month follow-up

  11. Improvement from baseline in NYHA classification at 30-day and 12-month follow-up.

    Time frame: 30-day and 12-month follow-up

  12. Change from baseline in LVMI at 30-day and 12-month follow-up.

    Time frame: 30-day and 12-month follow-up

07

Study locations

1 of 61 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2029, 38 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 38 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartActual
Oct 9, 2026was Jul 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
61 sites changed recruiting status (60 now not yet recruiting, 1 now recruiting)
Show 61 sites
  • The First Affiliated Hospital of Bengbu Medical University · Bengbu, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of University of Science and Technology of China · Hefei, Chinano status→Not yet recruiting
  • Affiliated Beijing Chaoyang Hospital of Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • Beijing Anzhen Hospital Affiliated to Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • Chinese People's Liberation Army General Hospital · Beijing, Chinano status→Not yet recruiting
  • Fuwai Hospital Chinese Academy of Medical Sciences · Beijing, Chinano status→Not yet recruiting
  • Peking University Third Hospital · Beijing, Chinano status→Not yet recruiting
  • Army Medical Center of the People's Liberation Army · Chongqing, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Army Medical University · Chongqing, Chinano status→Not yet recruiting
  • The Second Affiliated Hospital of Army Medical University · Chongqing, Chinano status→Not yet recruiting
  • Fujian Medical University Union Hospital · Fuzhou, Chinano status→Not yet recruiting
  • Fuzhou University Affiliated Provincial Hospital · Fuzhou, Chinano status→Not yet recruiting
  • The First Hospital of Lanzhou University · Lanzhou, Chinano status→Not yet recruiting
  • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Not yet recruiting
  • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Not yet recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
  • The First Affiliated Hospital, Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
  • Fuwai Huazhong Cardiovascular Hospital · Zhengzhou, Chinano status→Not yet recruiting
  • Henan Chest Hospital · Zhengzhou, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
  • Zhengzhou No.7 People's Hospital · Zhengzhou, Chinano status→Not yet recruiting
  • Renmin Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
  • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
  • The Second Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
  • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
  • Jiangsu Provincial People's Hospital · Nanjing, Chinano status→Not yet recruiting
  • Nanjing Drum Tower Hospital · Nanjing, Chinano status→Not yet recruiting
  • Nanjing First Hospital · Nanjing, Chinano status→Not yet recruiting
  • …and 31 more on the registry record
Oct 16, 2026
Start date
Jul 1, 2026→Oct 9, 2026 (actual)
Oct 16, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    61 sites changed recruiting status (60 now not yet recruiting, 1 now recruiting)
    Show 61 sites
    • The First Affiliated Hospital of Bengbu Medical University · Bengbu, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of University of Science and Technology of China · Hefei, Chinano status→Not yet recruiting
    • Affiliated Beijing Chaoyang Hospital of Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • Beijing Anzhen Hospital Affiliated to Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • Chinese People's Liberation Army General Hospital · Beijing, Chinano status→Not yet recruiting
    • Fuwai Hospital Chinese Academy of Medical Sciences · Beijing, Chinano status→Not yet recruiting
    • Peking University Third Hospital · Beijing, Chinano status→Not yet recruiting
    • Army Medical Center of the People's Liberation Army · Chongqing, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Army Medical University · Chongqing, Chinano status→Not yet recruiting
    • The Second Affiliated Hospital of Army Medical University · Chongqing, Chinano status→Not yet recruiting
    • Fujian Medical University Union Hospital · Fuzhou, Chinano status→Not yet recruiting
    • Fuzhou University Affiliated Provincial Hospital · Fuzhou, Chinano status→Not yet recruiting
    • The First Hospital of Lanzhou University · Lanzhou, Chinano status→Not yet recruiting
    • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Not yet recruiting
    • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Not yet recruiting
    • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
    • The First Affiliated Hospital, Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
    • Fuwai Huazhong Cardiovascular Hospital · Zhengzhou, Chinano status→Not yet recruiting
    • Henan Chest Hospital · Zhengzhou, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
    • Zhengzhou No.7 People's Hospital · Zhengzhou, Chinano status→Not yet recruiting
    • Renmin Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
    • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
    • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
    • The Second Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
    • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
    • Jiangsu Provincial People's Hospital · Nanjing, Chinano status→Not yet recruiting
    • Nanjing Drum Tower Hospital · Nanjing, Chinano status→Not yet recruiting
    • Nanjing First Hospital · Nanjing, Chinano status→Not yet recruiting
    • …and 31 more on the registry record
    Start date Jul 1, 2026→Oct 9, 2026 (now actual)
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07575672
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Oct 9, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Jian'an Wang, MD, PhD
Contact
wangjianan111@zju.edu.cn
+86-571-8778-4808

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion